Hirsch Andrew 4

What Happened

• Andrew Hirsch, a director of Editas Medicine (EDIT), was granted a derivative award of 51,700 shares (reported as $0.00 per share) on 2026-06-17. This was an award/grant (transaction code A), not an open‑market purchase or sale, so there was no immediate cash exchanged.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22 (5 days later).
• Reported price/value: $0.00 per share (derivative award); immediate cash value reported as $0.
• Award type: derivative (option/award). Footnote: the option was granted 6/17/2026 and is scheduled to vest in full on 6/17/2027.
• Shares owned after the transaction: not specified in the provided filing.
• Filing timeliness: filing occurred five days after the transaction date; insiders normally must file Form 4 within two business days, so this delay may exceed the typical reporting window.

Context

• This was a grant of an equity award that vests in one year — it is a compensation/retention event rather than a purchase or sale. Such awards are common for executives and directors and do not by themselves indicate immediate buying or selling intent. The award must vest before the insider can typically exercise or sell the underlying shares.